MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
0.5200
+0.0080
+1.56%
After Hours: 0.5198 -0.0002 -0.04% 19:56 12/06 EST
OPEN
0.5020
PREV CLOSE
0.5120
HIGH
0.5200
LOW
0.5020
VOLUME
603.61K
TURNOVER
0
52 WEEK HIGH
3.190
52 WEEK LOW
0.4126
MARKET CAP
99.20M
P/E (TTM)
-0.3349
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NKTR last week (1127-1201)?
Weekly Report · 3d ago
Nektar Therapeutics: Current report
Press release · 11/27 23:11
Weekly Report: what happened at NKTR last week (1120-1124)?
Weekly Report · 11/27 09:25
JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower
Jp morgan bullish on six big biotechs, rates nine others neutral or lower. Insmed, denali, immunocore, crinetics, mirum and biocryst among those rated overweight. Investment bank was less keen on cervel therapeutics, alkermes and esperion.
Seeking Alpha · 11/25 21:32
Nektar Therapeutics: Statement of changes in beneficial ownership of securities
Press release · 11/21 02:06
JP Morgan Reinstates Underweight on Nektar Therapeutics
Benzinga · 11/20 13:29
Weekly Report: what happened at NKTR last week (1113-1117)?
Weekly Report · 11/20 09:25
Nektar Therapeutics: Report of proposed sale of securities
Press release · 11/17 23:27
More
About NKTR
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in oncology and immunology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin (REZPEG) pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. REZPEG is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.